Medical Marijuana and Cannabis Healthcare Marketing Guide

Marketing a medical marijuana brand looks, at first, like marketing any other regulated healthcare service. There may be patients, clinicians, and product claims to review, but a state medical marijuana license brings advertising rules and platform restrictions of its own. Healthcare marketers already know how to work within limits like those, and most of the instinct carries over.

Cannabis marketing also depends on where and how a brand communicates. Channel eligibility must be assessed alongside the content itself, and those permissions are set by advertising platforms, state regulators, and local governments whose rules move independently of one another and change on their own timelines. A campaign should account for those permissions before creative and media plans are finalized.

Why Medical Marijuana Marketing Demands a Different Playbook Than the Rest of Healthcare

Healthcare marketing involves content, privacy, channel, and audience constraints. HIPAA governs what a provider can disclose about a patient, and the FDA and FTC govern what a brand can claim about a product or outcome. Those rules shape the creative and review process, while available media also depends on the organization, product, platform, and audience. A health system may use paid search, social, connected TV, and other media where the campaign and its targeting comply with applicable rules.

For cannabis product promotion, major platforms impose additional channel restrictions. Eligibility, claims, and state requirements should be checked at planning and again during review, especially after a regulatory change.

In April 2026, the Justice Department issued an order placing FDA-approved marijuana products and marijuana regulated by a state medical marijuana license in Schedule III of the Controlled Substances Act. Adult-use marijuana, bulk marijuana, product outside a qualifying state license, and synthetically derived THC all remain in Schedule I. The broader question of whether marijuana as a whole should move is still open. The DEA scheduled the hearing on that proposal to conclude no later than July 15, 2026, and a final decision on the broader proposal had not been announced in the cited DEA materials.

What matters to a marketing plan is that the platforms did not move when the law did. Advertising policy is written by the platform, not by the Controlled Substances Act, and a change in federal scheduling does not automatically unlock inventory that a platform has closed for its own reasons.

The second difference is structural. A national healthcare campaign must account for applicable federal and state rules. A cannabis campaign clears a platform layer, a state layer, and a local layer, and state requirements may call for different copy, disclosures, or placements across markets. Multi-state operators should plan market-specific reviews, which can affect production timelines and shared creative assets.

The third difference follows from the first two. When mainstream paid product ads are restricted, owned and earned channels may play a larger role. Their results should be assessed against the brand’s starting point, market, and measurement plan rather than a standard media-flight timeline.

The Three Layers of Cannabis Advertising Restriction: Federal Platforms, State Law, and Local Rules

A cannabis campaign must account for platform policy, state law, and applicable local rules. A brand can satisfy one and be blocked by another, and the applicable requirements should be checked in each market.

The first layer is the platform policy. Google, Meta, and other platforms publish separate advertising policies and review the ad, imagery, and destination page. These policies are commercial decisions rather than legal requirements, which is why they did not shift when federal scheduling did. A federal scheduling change does not by itself revise those policies.

The second layer is state law, which can add license-specific advertising requirements. States that permit medical marijuana may attach different advertising conditions to a license, so a campaign approved in one market should not be assumed compliant in another. Florida provides a current example. Under Rule 64ER25-6, Florida adopted an emergency advertising and marketing rule for medical marijuana treatment centers. The state has also proposed a nonemergency replacement, Rule 64-4.227. For an MMTC planning a campaign, the current operative rule and replacement status determine what placements, content, and approvals are allowed.

The third layer is local. Applicable municipal and county requirements can affect signage and other physical placements, and may differ among locations. A brand with multiple locations should review the rules applicable to each location.

These layers add planning steps for cannabis campaigns. Each layer is individually manageable. Together, they mean the compliance question has to be answered before the creative brief is written, because a concept that survives platform review can still be prohibited by state rule, and a concept that satisfies both can still be unbuildable at a specific location.

What Restricts Cannabis Product Ads on Google and Meta in 2026?

Google’s recreational drugs policy prohibits ads promoting the sale of cannabis. Google separately allows qualifying topical hemp-derived CBD ads with THC content of 0.3% or less. FDA-approved pharmaceutical CBD advertisers must apply and may target only California, Colorado, and Puerto Rico; retailers should review Google’s separate certification conditions. Google runs a separate Search-only pilot for legal cannabis products in Canada through December 31, 2026, which is limited to that market and does not extend to United States advertisers.

Meta applies a comparable prohibition. Its advertising standards state that ads may not promote or offer the sale of THC products or cannabis products containing related psychoactive components. Meta provides a separate authorization route for certain CBD ads, subject to its current certification, targeting, and age requirements.

The common misreading is that federal rescheduling changed this. It did not. Platform advertising policy is set by the platform for its own commercial and brand safety reasons, and it moves on its own schedule rather than tracking the Controlled Substances Act.

Planning Paid Media When Major Platforms Restrict Cannabis Product Ads

Paid media can support healthcare campaigns, but cannabis product promotion has fewer mainstream platform options. A cannabis media plan should identify eligible inventory, its audience, and the results it can reasonably measure before assigning it a growth target.

Eligible options may include endemic publishers, dispensary-finder platforms, compliant out-of-home placements, and networks that accept cannabis advertising. Each has different reach, audience intent, costs, and approval conditions. Test those characteristics against the campaign objective rather than assuming a channel can only capture existing demand or can carry growth on its own.

Owned and earned channels can complement eligible paid placements: search visibility, the website itself, reputation and review presence, email and SMS to an owned list, and the community relationships that produce referrals. Their effects can build over time, so budgets and expectations should reflect the brand’s baseline and the work needed to improve those assets.

Platform policies may treat independent public education differently from ads promoting a cannabis product for sale. Meta’s standards permit ads that refer to prohibited substances for the purposes of political advocacy, news, and awareness campaigns, provided they do not promote the sale or consumption of those substances. A state health department, university, or public health organization may have a path to advertise factual education, subject to the platform’s review and applicable law.

That distinction depends on the advertiser, ad, destination, and surrounding purchase pathway. Avoid product promotion or imagery encouraging consumption in an awareness campaign, and confirm eligibility with the platform before launch. Allow time for review and plan alternative placements if a campaign is rejected. An educational label alone does not guarantee approval, especially when a commercial brand is the advertiser.

For commercial brands, scope paid and owned channels according to eligible placements, audience intent, and observed performance. Keep product advertising separate from independent public-health education when evaluating platform policy.

Communicating Health Claims Responsibly: What Cannabis Marketing Can and Cannot Say

FDA drug-approval rules and FTC advertising-substantiation standards both matter when a brand makes health claims.

The FDA governs whether a product is being marketed as a drug. Under the Federal Food, Drug, and Cosmetic Act, a product intended to treat a disease or to affect the structure or function of the body is a drug, and therapeutic claims for an unapproved product can lead the FDA to treat it as an unapproved drug. A state medical marijuana license is not FDA approval. That framing drives the agency’s enforcement, and its warning letters have consistently cited products that claim to cure, mitigate, treat, or prevent various diseases as the violation. The agency has applied the same analysis to delta-8 THC products marketed as unapproved treatments for medical conditions, showing that hemp-derived products also face federal claim scrutiny.

The FTC governs advertising, and its standard is substantiation rather than approval. The agency’s position is that health claims require competent and reliable scientific evidence, and it has enforced that against cannabis marketers directly. In December 2020, the FTC announced its first law enforcement crackdown on deceptive CBD claims, taking action against six sellers over unsupported assertions about treating cancer, heart disease, hypertension, and Alzheimer’s disease. The settlements barred future deceptive advertising and required scientific evidence for any health claim. The agency followed with additional cases and made clear that the sweep was not the end of its interest in the category.

Condition-specific language deserves careful review. Naming a disease and implying that an unapproved product treats it can invite enforcement; a physician recommendation, testimonial, or blog format does not automatically substantiate that claim. Enforcement has reached the website copy and social media, as well as packaging.

Brands can describe products accurately, explain a state’s qualifying-condition framework as a matter of law rather than a therapeutic promise, point patients to licensed physicians who make individual determinations, and publish educational materials on lawful access, safe handling, and the difference between regulated and unregulated products. Brand-published education still needs review for implied therapeutic claims and promotional context. Independent public-health education is a separate case; neither category is exempt merely because its copy is described as educational.

How Should Cannabis Brands Evaluate Health Claims?

For an unapproved cannabis or CBD product, claims that it can prevent, diagnose, mitigate, treat, or cure a disease may trigger FDA enforcement because the FDA treats such claims as marketing an unapproved new drug under the FD&C Act. The FTC applies a parallel advertising standard requiring competent and reliable scientific evidence behind any health claim, and its enforcement has targeted assertions about cancer, Alzheimer’s disease, diabetes, chronic pain, and other serious conditions. A marketing review should include website copy, testimonials, social posts, and packaging; the context and implied claim matter.

Medical Marijuana Marketing Versus Pharmaceutical Marketing: Shared Constraints, Different Playbooks

Prescription drug and state-licensed medical marijuana advertising have different approval and media requirements. A state license does not give a cannabis product FDA-approved drug labeling.

Pharmaceutical marketing is heavily regulated in what it can say. Under 21 CFR 202.1, a prescription drug advertisement must present required information on effects, risks, and contraindications, and it fails that test if effectiveness information is presented with greater scope, depth, or detail without a fair balance with the risk information. Broadcast prescription drug ads must present a major statement of side effects and contraindications; a brief summary is required unless adequate provision is made to disseminate the approved or permitted labeling. The applicable format and disclosure rules shape how each ad is produced.

FDA-approved prescription drugs may use mainstream media when their ads satisfy applicable disclosure, platform, and targeting rules. The channel plan remains subject to review.

A state medical marijuana license is not FDA drug approval and does not create FDA-approved labeling for that product. FDA provides a drug-development and approval process for cannabis-derived medicines, but state-licensed products should not be described as FDA-approved drugs. Their advertising must satisfy applicable state requirements and platform policies as well as claim standards.

Medical, legal, and regulatory review and claim substantiation remain useful disciplines. For cannabis product advertising, add a channel-eligibility assessment and market-specific review early enough to inform the creative brief.

The shared ground is real, though. Both categories are held to substantiation standards on health claims, both face agencies that read website copy and social posts as advertising, and both operate where a single unsupported sentence can trigger enforcement. Marketers coming from pharmaceutical or medical device backgrounds bring a genuinely relevant discipline. Approval of the copy should be paired with confirmation that the placement is eligible.

How Does Marketing a Medical Marijuana Brand Differ From Marketing a Pharmaceutical Brand?

FDA-approved prescription drugs carry specific disclosure obligations and may access mainstream channels subject to applicable rules. State-licensed medical marijuana product ads face different state and platform requirements. Prescription drug advertising is governed by 21 CFR 202.1, which requires a fair balance between effectiveness and risk information and a brief summary of side effects and contraindications, obligations that apply because the drug has been through FDA approval and has approved labeling. State medical marijuana licensure is distinct from FDA drug approval, and the product’s advertising must be reviewed for claims, state requirements, and placement eligibility.

Local SEO, Reputation, and AI Search Visibility

When major paid platforms restrict product ads, local search is one useful way for prospective patients to discover a dispensary. Someone deciding where to go searches by proximity and intent, and the results they see are shaped by the business profile, the review corpus, and the site behind it. These organic assets do not require approval as paid platform ads, though their content must still comply with applicable rules.

Local search infrastructure is a useful starting point. An accurate, complete business profile with correct hours, service areas, product categories, and current photography helps searchers find accurate location information and evaluate a listing. Consistency across directories and data aggregators matters for the same reason it always has, especially where mainstream paid product promotion is restricted.

Reviews can also help prospective patients evaluate a location. New patients arrive uncertain, often navigating a first purchase in a regulated system they don’t fully understand, and reviews can help them understand what to expect. Review content and responses may inform a prospective patient’s decision. State rules constrain how a brand may solicit and respond, particularly where regulators treat promotional language as advertising, so review programs need the same compliance review as the rest of the marketing does.

The site itself is doing more work than it used to, because search increasingly answers questions without sending a click. Pew Research Center’s behavioral study of 900 US adults found that 58% conducted at least one Google search in March 2025 that produced an AI-generated summary, and that users clicked a traditional result link in 8% of visits when a summary appeared, compared with 15% when one did not. That is a general search finding, not evidence of a cannabis-specific traffic effect. It supports reviewing how a brand’s content appears in search results and AI summaries.

For cannabis brands, the practical response is to build content that answers the questions patients actually ask, in a structure that generative systems can extract: how the state’s program works, what qualifying conditions mean under the law, what a first visit involves, and how regulated products differ from unregulated hemp-derived alternatives. Explanatory content can avoid unsupported therapeutic promises, but a commercial brand should review its claims, links, and promotional context before publication.

The honest limitation is that visibility in AI answers is harder to measure than rankings were, and brands can track presence and citation as diagnostic signals while measuring website and business outcomes separately.

Which Marketing Channels Actually Work for Cannabis Brands When Paid Advertising Is Restricted?

The channels that work are the ones a brand owns or earns: local search and business profile optimization, review and reputation management, the website itself, email and SMS to an opted-in list, and content built to be surfaced by generative search. Their relative value depends on a brand’s market and results. Eligible paid placements can serve different objectives, including reaching people with existing category intent. Test their contribution rather than assigning them a fixed role.

What to Look for in a Marketing Agency With Cannabis and Regulated Healthcare Experience

Relevant cannabis work can be one useful qualification. Also ask for evidence that the team assesses channels, reviews claims, documents approvals, and adapts creative across markets.

First, ask whether an agency assesses channel eligibility before developing creative. Ask how a prospective partner would sequence a campaign, and listen for whether platform policy, state rule, and local ordinance get resolved at the planning stage or treated as a legal review at the end. The answer should show how placement eligibility informs the creative brief.

Second, ask whether the agency can document its compliance process. In a category where a state regulator can require approval of internet advertising, documentation is a deliverable rather than an internal habit. Ask to see how the team records submissions, approvals, platform rejections, and approved alternatives.

Third, test claim discipline. Any agency working in this space should be able to explain, without prompting, where the line sits between describing a product and making a therapeutic claim, and how that line applies to testimonials, blog content, and social posts rather than only to packaging. Ask when claim review occurs and who has authority to approve the final wording.

Fourth, test measurement realism. Ask a prospective partner how it sets timelines and measures paid, owned, and earned activity against an agreed baseline.

Multi-state operators should add one more criterion, which is whether the agency can run parallel compliance tracks without duplicating the entire production process in every market. That capability is operational rather than creative, and can be tested through examples of multi-market work.

For organizations planning regulated healthcare campaigns, evok’s healthcare marketing practice can support channel planning, claim review, and market-specific execution.

What Should a Healthcare or Cannabis Brand Look for When Hiring a Marketing Agency?

Evaluate relevant category work alongside the team’s regulatory and operational process. Specifically, ask how the agency resolves platform advertising policy, state advertising rules such as Florida’s requirements for medical marijuana treatment centers under Rule 64ER25-6, and local ordinances before creative development begins, how it documents approvals and rejections, and how it applies health claim standards to website copy and social content rather than only to packaging.

Building a Compliant Marketing Foundation That Holds Up as Cannabis Regulation Keeps Changing

Federal scheduling and state advertising rules may change on different timelines. Build a process that can adapt when the operative rule or a platform policy changes.

Owned assets give a brand channels it can maintain and improve. A website, an email list, a review presence, and a library of educational content belong to the brand and do not depend on a platform’s willingness to accept the spend. Those assets can support eligible paid activity and keep essential information available when placements change. Their contribution should be measured rather than assumed.

Compliance documentation also supports continuity and review. A brand that maintains records of what it submitted, what each platform and regulator approved or rejected, and how the creative was adjusted in response has an institutional memory that survives staff turnover and agency transitions. It also has the evidentiary record it needs if a regulator asks. In a category where advertising approval can be a licensing condition, that record has direct operational value.

The third element is a monitoring practice with a defined owner. Platform policies and state rules can change, while the timing of pending federal action remains uncertain. Someone should be responsible for checking published platform policies and state regulator notices on a set cadence and flagging what changes, rather than discovering a shift when a campaign is rejected.

The fourth is modular creative. Assets built so that claims, disclosures, and imagery can be adjusted per market without reshooting or rebuilding are cheaper to bring into compliance when a rule moves. This production decision can reduce the work needed when a rule changes.

What none of this assumes is a particular outcome. Full rescheduling would not automatically open Google and Meta, because platform policy is set independently of federal scheduling, as the partial reclassification in April demonstrated. It might eventually influence those policies, and it might not. State advertising rules would remain in force either way, and Florida’s emergency rule and proposed replacement should be monitored separately from federal scheduling.

Treat regulatory change as a planning input. Recheck current rules, approved placements, and creative before assuming that a federal change permits a new campaign.

Frequently Asked Questions About Medical Marijuana and Cannabis Healthcare Marketing

Does federal cannabis rescheduling mean brands can start running paid ads on Google or Meta?

No. Platform advertising policies are commercial decisions made by each platform, and they do not automatically follow federal scheduling. The April 2026 order moved FDA-approved marijuana products and marijuana under a qualifying state medical license to Schedule III, and the advertising policies at Google and Meta continued to prohibit ads promoting cannabis sales afterward. A future policy change is possible, but brands should plan against published platform rules rather than against anticipated ones.

How long does it typically take for a cannabis brand’s SEO and content strategy to show results?

There is no universal timeline. Profile updates may improve the accuracy of a listing quickly, while content and search visibility can take longer to evaluate. Any timeline estimate depends on market competitiveness, the site’s existing footing, and how much foundational cleanup is required before new work can be performed.

Do medical marijuana marketing rules differ from recreational cannabis marketing rules?

Yes, and the gap widened in 2026. Federally, marijuana under a qualifying state medical license moved to Schedule III while adult-use marijuana remained in Schedule I, so the two now sit in different positions under the Controlled Substances Act. At the state level, medical and adult-use programs frequently carry separate advertising rules, and a state may impose tighter restrictions on one than the other. Platform policies, by contrast, have generally not drawn this distinction.

Which states currently allow the most flexibility in cannabis marketing and advertising?

Flexibility varies along several axes rather than on a single scale, so the useful comparison is structural. States differ in whether they permit advertising beyond the licensee’s own channels, whether creative requires regulatory pre-approval, how they treat imagery and endorsement, and what audience-composition thresholds apply to placement. Florida’s emergency rule imposes MMTC advertising requirements, and a nonemergency replacement has been proposed. Verify the current operative text before specifying permitted internet channels. Brands operating across multiple states should assume the answer changes by market and verify current rules with each state’s regulator rather than relying on a national summary.

Is educational content about medical marijuana treated differently than promotional content under advertising rules?

Often, yes, though the distinction has to be real rather than cosmetic. Meta’s advertising standards, for example, permit references to prohibited substances for news and awareness campaigns as long as the ad does not promote sale or consumption. Content that explains a state’s legal framework, patient eligibility, or product safety without promoting a specific product sits in a different posture than brand advertising. The advertiser, destination, purchase pathways, and imagery also matter. A commercial brand should not assume that calling its product content educational makes it eligible for an awareness-ad allowance.

Can a marketing agency serve both cannabis clients and mainstream healthcare clients without a conflict of interest?

It depends on client agreements, accounts, and procurement restrictions. The relevant questions are whether the agency maintains separation between accounts that could compete with each other, whether any client contract restricts category work, and whether the agency’s regulated-category experience genuinely transfers. Some public sector and health system clients impose their own restrictions on vendor rosters, so the question is worth raising directly during procurement rather than assuming.